Physiologically Based and Population Pharmacokinetic Modeling of Midazolam in Children With Obesity Using Real‐World Data
Clinical and Translational Science · 2025
DOI: 10.1111/cts.70247 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Science, 2025. Verfasst von Sean McCann und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, Chapel Hill, North Carolina, USA. Hauptthemen laut MEDLINE: Midazolam, Models, Biological, Pediatric Obesity, Hypnotics and Sedatives. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCATS NIH HHS, NICHD NIH HHS, Eunice Kennedy Shriver National Institute of Child Health and Human Development.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Children represent a highly complex and variable population for treatment, including interindividual differences in drug dose–exposure. Midazolam has been used as a sedative for hospitalized children on‐ and off‐label; however, factors affecting interindividual variability (IIV) in observed clearance for this population are not fully understood and can result in extreme under‐ or overexposure. Obesity has been described as a significant influence on midazolam in adolescents, which could potentially alter drug exposure. The goal of this study was to use two modeling strategies to evaluate dose–exposure of midazolam in children with and without obesity. Population pharmacokinetic modeling assessed whether measures of obesity status would explain some of the observed IIV for midazolam clearance. In all, 164 plasma concentrations were collected from 93 participating children, many with obesity. Covariate modeling did not identify any factors influential to clearance beyond body weight. Model IIV was similar to that observed in previous models of critically ill children (coefficient of variation, 175%) along with considerable residual unexplained variability (50.4%). Then, a previously published virtual population of children with obesity was incorporated into an existing physiologically based pharmacokinetic model of midazolam in the open‐source PK‐Sim software. Dosing simulations for a subset of 46 participants demonstrated minor overpredictions in children with obesity compared to those without. Both models predicted a minor (< 20%) increase in exposure for children with obesity given the same weight‐based dose. This research demonstrates the use of population pharmacokinetics combined with physiologically based pharmacokinetic modeling to compare simulated exposures in children with and without obesity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, Chapel Hill, North Carolina, USA.
- Duke Clinical Research Institute, Durham, North Carolina, USA.
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, USA.
- Children's National Hospital, Washington, DC, USA.
- Oregon Health and Science University, Portland, Oregon, USA.
- Division of Critical Care, Department of Pediatrics, Nemours Children's Hospital, Wilmington, Delaware, USA.
ORCID-Profile: Sean McCann, Victória E Helfer, Stephen J Balevic, William J Muller, John N van den Anker, Amira Al-Uzri, Marisa L Meyer, Sarah G Anderson, Andrea N Edginton, Daniel Gonzalez
Förderung
- NCATS NIH HHS
- NICHD NIH HHS
- Eunice Kennedy Shriver National Institute of Child Health and Human Development
Zitieren
APA
McCann, S., Helfer, V. E., Balevic, S. J., Muller, W. J., van den Anker, J. N., Al-Uzri, A., Meyer, M. L., Anderson, S. G., Turdalieva, S., Edginton, A. N., Gonzalez, D., & Best Pharmaceuticals for Children Act Pediatric Trials Network Steering Committee (2025). Physiologically Based and Population Pharmacokinetic Modeling of Midazolam in Children With Obesity Using Real‐World Data. Clinical and Translational Science. https://doi.org/10.1111/cts.70247
Vancouver
McCann S, Helfer VE, Balevic SJ, Muller WJ, van den Anker JN, Al-Uzri A, et al. Physiologically Based and Population Pharmacokinetic Modeling of Midazolam in Children With Obesity Using Real‐World Data. Clinical and Translational Science. 2025. doi:10.1111/cts.70247
BibTeX
@article{McCann2025,
author = {McCann, Sean and Helfer, Victória E and Balevic, Stephen J and Muller, William J and van den Anker, John N and Al-Uzri, Amira and Meyer, Marisa L and Anderson, Sarah G and Turdalieva, Sitora and Edginton, Andrea N and Gonzalez, Daniel and Best Pharmaceuticals for Children Act Pediatric Trials Network Steering Committee, Best Pharmaceuticals for Children Act Pediatric Trials Network Steering Committee},
title = {Physiologically Based and Population Pharmacokinetic Modeling of Midazolam in Children With Obesity Using Real‐World Data},
journal = {Clinical and Translational Science},
year = {2025},
doi = {10.1111/cts.70247}
}
EUVIMED